Aridis Pipeline
Aridis is discovering and developing highly differentiated drug candidates to prevent and treat life-threatening infectious diseases that overcome the threat of AMR and global viral outbreaks, with both therapeutic monoclonal antibodies and novel anti-infectives designed to complement the current standards of care.
- Hospital Acquired Infections (Ventilator Associated Pneumonia)
- Cystic Fibrosis
- Blood Stream Infections
- COVID-19 viral infection
| Products | Targets | Indication | Pre-Clinical | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| Wholly Owned Products | |||||||
| AR-301 mAb (Tosatoxumab) | Gram (+) Bacteria S.aureus -toxin |
Treatment of S.aureus Ventilator Assoc. Pneumonia (VAP) | |||||
| AR-320 mAb (Suvratoxumab) | Gram (+) Bacteria S.aureus -toxin |
Prevention of S.aureus Ventilator Assoc. Pneumonia (VAP) | |||||
| AR-501 (Panaecin™) | Gram (-) & (+) Bacteria Iron Acquisition Systems |
Treatment of Cystic Fibrosis Lung Infections | |||||
| AR-701 mAbs | Spike RBD | COVID-19 | |||||
| AR-401 mAb | Gram (-) Bacteria A.baumannii |
Bacteremia | |||||
| Partnered Products | |||||||
| AR-105 mAb (Aerucin™) | Gram (-) Bacteria P.aeruginosa Alginate |
Pneumonia HAP/VAP | |||||
| AR-101 mAb (Aerumab™) | Gram (-) Bacteria P.aeruginosa LPS 011 |
Pneumonia HAP/VAP | |||||
| AR-201 mAb | Resp. Synctial Virus | RSV | |||||
| Drug | Target | Indication | Stage |
|---|---|---|---|
| Wholly Owned Products | AR-301 mAb (Tosatoxumab) | Gram (+) Bacteria S.aureus -toxin |
Treatment of S.aureus Ventilator Assoc. Pneumonia (VAP) | Phase 3 |
| AR-320 mAb (Suvratoxumab) | Gram (+) Bacteria S.aureus -toxin |
Prevention of S.aureus Ventilator Assoc. Pneumonia (VAP) | Phase 2 |
| AR-501 (Panaecin™) | Gram (-) & (+) Bacteria Iron Acquisition Systems |
Treatment of Cystic Fibrosis Lung Infections | Phase 2 |
| AR-701 mAbs | Spike RBD | COVID-19 | Pre-Clinical |
| AR-401 mAb | Gram (-) Bacteria A.baumannii |
Bacteremia | Indication |
| Partnered Products | AR-105 mAb (Aerucin™) | Gram (-) Bacteria P.aeruginosa Alginate |
Pneumonia HAP/VAP | Phase 2 |
| AR-101 mAb (Aerumab™) | Gram (-) Bacteria P.aeruginosa LPS 011 |
Pneumonia HAP/VAP | Phase 2 |
| AR-201 mAb | Resp. Synctial Virus | RSV | Indication |
Fully human monoclonal antibodies (mAb) directed against infectious disease targets is a growing area of drug development interests. Anti-infective mAbs is a new class of anti-infective that has the potential to be standard of care treatments due to their strong safety profile in humans, remarkably long plasma half-life, and low risk of drug resistance.
Aridis has developed a suite of human mAbs as anti-infective drugs targeting key human pathogens, including S. aureus (MRSA & MSSA), P. aeruginosa, A. baumannii bacteria, and respiratory syncytial virus. Complementing these mAbs is a broad spectrum anti-infective candidate based on the unique iron analog properties of gallium (Panaecin®).